CLAIRE

Predicting Infectious Disease Progression and Outcomes with Metagenomics and AI

At Lifetime Omics, we work hard to impact communities and fight infectious diseases with technology and science. 

With our CLAIRE platform, we predict the severity of viral diseases like COVID-19 using metagenomics and AI, providing personalized information to physicians in their treatment decisions to help improve health outcomes and better use healthcare resources.

While the initial struggles of distinguishing severe from mild COVID-19 cases have lessened with improved understanding and treatment protocols, healthcare professionals still face critical triage decisions during pandemics and seasonal outbreaks like influenza. Deciding on hospital admissions, ICU placements, and optimal treatment remains a crucial yet challenging task. Though influenza’s annual impact is significant, averaging 389,000 deaths globally, the emergence of COVID-19 highlighted the urgent need for better predictive tools. Accurately identifying individuals at higher risk of severe respiratory illness, whether from COVID-19, influenza, or other emerging threats, could significantly reduce mortality rates and optimize resource allocation during outbreaks.

Our solution for any pandemic and future seasonal outbreaks is CLAIRE. CLAIRE stands for CLuster AI PREdiction of infectious respiratory disease progression through artificial intelligence and metagenomics. 

There are 2 technologies at the core of CLAIRE: 

1. Metagenomics AI is the biotechnology coupled with AI that sequences the genetic material (DNA or RNA) in saliva samples taken from infected patients. CLAIRE’s AI can then identify bacterial and viral clusters that correlate with disease progression
2. EHR AI is used to model patterns of disease progression from hospital electronic health records (EHR)

These two technologies are then applied to:

3. Hospital Monitoring to guide doctors in their decision making
4. Telemedicine by guiding patients at home who have mild symptoms or are recovering.

Innovation through AI, Metagenomics, and Phylogenetics 

The core innovation in CLAIRE is the AI-driven analysis of the saliva metagenome to discover the genetics of COVID-19, Influenza, rhinoviruses, and other infectious respiratory viruses and can provide information of their interaction and inform disease progression, such as for example how quickly the virus is evolving inside a person’s body. CLAIRE will also identify clusters of pathogenic or bad bacteria, clusters of good bacteria, and clusters of other viruses, which should all give a more accurate picture of the health of a patient.

Here in South Florida, our strong international tourism exposes us to viral dangers and Social Determinants of Health (SDOH) always present challenges to our most vulnerable populations. CLAIRE can predict the geographic origin of the transmission and help to slow down new outbreaks by reporting the information to public health agencies.

CLAIRE EHR uses AI to analyze medical records

The second innovation of CLAIRE is that it combines metagenomics with AI-driven analysis of Electronic Health Records by applying machine learning to the multi-dimensional vector of health data from hospital patients to identify the best measurements or information that helps predict if a person is at risk of being a critical case or not. CLAIRE can be also applied to the analysis of EHR, and Lifetime Omics is pursuing new partnerships to offer CLAIRE’s services to hospitals that do not have access to a metagenomics sequencing lab.

CLAIRE is a Health-As-A-Service (HAAS) platform that will offer health status and disease progression predictive services to:

1. Hospitals, Primary Care Practices and large Health Systems
2. Public Health Organizations
3. Health Insurance Companies 
4. Self-insured Companies 

The CLAIRE team is dedicated to further develop this technology to help health systems with better resource allocation and guidance in patient care, and to slow down outbreaks by reporting findings to health agencies.